# Genmab A/S (GMAB)

> Source: Nexqual · https://nexqual.com/GMAB · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Genmab A/S (GMAB), nexqual.com/GMAB" · informational, not investment advice.

**Price:** USD 40 (+1.09% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 39.57 · day 39.5–40.17 · 52w 23.62–40.17 · market cap $24.6B · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 45.04 (range 33.5–58).
- Total return with dividends: 1Y +33.9% vs S&P 500 +14.9%; 5Y -14.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.31, revenue estimate $8.00B.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 45.04 (low 33.5, high 58).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Truist Securities | Target raised | Buy | $40 → $45 |
| 2026-10-07 | Guggenheim | Target raised | Buy | $54 → $58 |
| 2026-10-07 | HC Wainwright & Co. | Target raised | Buy | $40 → $50 |
| 2026-10-05 | Guggenheim | Target raised | Buy | $45 → $54 |
| 2026-09-14 | HC Wainwright & Co. | Reiterated | Buy | $40 |
| 2026-08-07 | Guggenheim | Target raised | Buy | $40 → $42 |
| 2026-07-22 | TD Cowen | Upgrade | Hold → Buy | $32 → $43 |
| 2026-07-02 | HC Wainwright & Co. | Target raised | Buy | $38 → $40 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +33.9% | -14.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +34.0% | -3.0% |
| Volatility (annualized) | 34.1% | 33.5% |
| Max drawdown | -32.5% (Jan 2026→Jun 2026) | -60.9% (Nov 2022→Mar 2025) |

## Peers (Biotechnology)
INCY (Incyte Corporation) USD 116.93 +3.08% · BNTX (BioNTech SE) USD 89.67 -1.77% · ROIV (Roivant Sciences Ltd.) USD 37.45 +1.77% · INSM (Insmed Incorporated) USD 95.06 +1.08% · ALNY (Alnylam Pharmaceuticals, Inc.) USD 227.28 +0.97% · RPRX (Royalty Pharma plc) USD 63.75 +2.57%

## More
Full page: https://nexqual.com/GMAB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in GMAB's own 20-F filed 2026-02-17 (https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231_d2.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Pfizer (PFE) | "pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining" |
| Partner | AbbVie (ABBV) | "pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining" |
| Partner | Novo Nordisk (NVO) | "These include products that are being developed in collaboration with Lundbeck, Novo Nordisk and" |
| Partner | Seagen | "In October 2011, we entered into a license and collaboration agreement with Seagen, Inc. ("Seagen"), now Pfizer per" |
| Partner | AMGEN INC (AMGN) | "Roche / Amgen Teprotumumab Collaboration" |
| Related party | Eli Lilly (LLY) | "Mr. Hoffmann has held a variety of sales and marketing and executive management positions at Eli Lilly and Company" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.31 | $0.35 | -9.1% | $8.00B | 5 |
| Next quarter (ends 2026-12-31) | $0.24 | $0.35 | -30.0% | $8.41B | 5 |
| Current fiscal year (ends 2026-12-31) | $1.17 | $0.00 | — | $29.76B | 1 |
| Next fiscal year (ends 2027-12-31) | $1.51 | $0.00 | — | $35.34B | 2 |